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The epithelial-mesenchymal transition (EMT) is a complex process in which cell
phenotype switches from the epithelial to mesenchymal one. The deregulations of this
process have been related with the occurrence of different diseases such as lung cancer
and fibrosis. In the last decade, several efforts have been devoted in understanding the
mechanisms that trigger and sustain this transition process. Adenosine is a purinergic
signaling molecule that has been involved in the onset and progression of chronic
lung diseases and cancer through the A2B adenosine receptor subtype activation,
too. However, the relationship between A2BAR and EMT has not been investigated,
yet. Herein, the A2BAR characterization was carried out in human epithelial lung cells.
Moreover, the effects of receptor activation on EMT were investigated in the absence
and presence of transforming growth factor-beta (TGF-β1), which has been known
to promote the transition. The A2BAR activation alone decreased and increased the
expression of epithelial markers (E-cadherin) and the mesenchymal one (Vimentin,
N-cadherin), respectively, nevertheless a complete EMT was not observed. Surprisingly,
the receptor activation counteracted the EMT induced by TGF-β1. Several intracellular
pathways regulate the EMT: high levels of cAMP and ERK1/2 phosphorylation has
been demonstrated to counteract and promote the transition, respectively. The A2BAR
stimulation was able to modulated these two pathways, cAMP/PKA and MAPK/ERK,
shifting the fine balance toward activation or inhibition of EMT. In fact, using a selective
PKA inhibitor, which blocks the cAMP pathway, the A2BAR-mediated EMT promotion
were exacerbated, and conversely the selective inhibition of MAPK/ERK counteracted
the receptor-induced transition. These results highlighted the A2BAR as one of the
receptors involved in the modulation of EMT process. Nevertheless, its activation is not
enough to trigger a complete transition, its ability to affect different intracellular pathways
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could represent a mechanism at the basis of EMT maintenance/inhibition based on the
extracellular microenvironment. Despite further investigations are needed, herein for the
first time the A2BAR has been related to the EMT process, and therefore to the different
EMT-related pathologies.
Keywords: adenosine A2B receptor, epithelial mesenchymal transition, lung, MAPK-ERK, cAMP-PKA,
transforming growth factor-β1
INTRODUCTION
The epithelial-mesenchymal transition (EMT) is an
evolutionarily conserved biochemical process in which cells
undergo conversion from an epithelial to a mesenchymal
phenotype. The EMT is characterized by the loss of the epithelial
cell–cell adhesion molecule CDH1 (E-cadherin), and/or a
concomitant gain of mesenchymal markers such as CDH2
(N-cadherin), VIM (Vimentin), and/or αSMA (alpha-smooth
muscle actin) (Nieto et al., 2016; Singh et al., 2017). EMT is a
Janus-faced process due to its pivotal role in embryogenesis and
wound healing and in the development of chronic pathologies,
such as fibrosis and cancer (Lamouille et al., 2014).
The EMT process has been widely correlated with lung
embryogenesis (Lee et al., 2006) and cancer (Sung et al.,
2016; Legras et al., 2017), but it has only recently been
linked to chronic human lung and airway diseases such as
chronic obstructive pulmonary disease (COPD) and idiopathic
pulmonary fibrosis (IPF) (Willis et al., 2006; Sohal and Walters,
2013; Jonsdottir et al., 2015; Jolly et al., 2017). In fact, it has
been proposed that alveolar epithelial cells (AECs), undergoing
EMT (De Maio et al., 2012; Yamaguchi et al., 2017) or partial
EMT (Morbini et al., 2011), are a source of extracellular
matrix-producing fibroblasts/myofibroblasts. It has been widely
accepted that several soluble factors such as, growth factors
[fibroblast growth factor (FGF), epidermal growth factor (EGF)]
and inflammatory cytokines (transforming growth factor-beta
(TGF-β1), interleukin-6 (Il-6), tumor necrosis factor-alpha
(TNF-α), could trigger and promote the EMT (Nieto et al.,
2016; Suarez-Carmona et al., 2017). In the lung, attention has
been focused on TGF-β1, which has been found to promote
AEC differentiation (Yang et al., 2014; Shi et al., 2016) and the
aggressiveness of cancer cells (Sakuma, 2017).
Adenosine is a soluble factor involved in physiological
processes; however, after tissue injury, its levels rise to
micromolar concentration promoting anti-inflammatory action
(Ohta and Sitkovsky, 2001). Recently, a correlation between
the increase in adenosine levels and the EMT process has
been reported (Guillén-Gómez et al., 2012; Lu and Insel,
2014; Gao et al., 2016). Adenosine binds to four specific
cell membrane G-protein-coupled receptors (GPCRs) known
as adenosine receptors (ARs): A1, A2A, A2B, and A3. In this
context, great attention has been focused on the purine receptor
involvement in the EMT process. Only a few studies have
correlated the EMT and purinergic receptors P2X and P2Y,
such as P2X7, P2Y2, P2Y6, and P2Y12 (review in Martínez-
Ramírez et al., 2017). Furthermore, some evidence has correlated
the adenosine receptor A2A with the transition (Xiao et al.,
2013). However, no evidence has been reported on the role of
the A2BAR subtype in the trigger or modulation of induced-
EMT.
The A2BAR subtype has been recently linked to cancer
aggressiveness (Mittal et al., 2016; Sepúlveda et al., 2016) and
fibrotic processes of the heart (Ryzhov et al., 2014; Phosri
et al., 2017), kidney (Roberts et al., 2014; Wilkinson et al.,
2016) and lung (Zhou et al., 2011; Karmouty-Quintana et al.,
2012; Karmouty-Quintana et al., 2013). A2BAR couples to Gαs
proteins, resulting in the activation of adenylyl cyclase (AC)
and an increase in intracellular cyclic AMP (cAMP) levels
that subsequently activate protein kinase A (PKA) (Schulte
and Fredholm, 2003; Sun and Huang, 2016). However, A2BAR
can also coupled to the Gq-PLC pathway and induces the
activation of mitogen-activated protein kinase (MAPK) (Schulte
and Fredholm, 2003; Sun and Huang, 2016). In fact, A2BAR
induces the phosphorylation of ERK1/2 in human umbilical vein
endothelial cells (HUVECs) (Fang and Olah, 2007), human mast
cell line (MHC-1 cells) (Feoktistov et al., 1999), and human
retinal endothelial cells (HRECs) (Grant et al., 2001). The cAMP
role in EMT promotion/blockade is debatable. Pattabiraman
et al. (2016) reported that a PKA activator could lead to
a mesenchymal-epithelial transition as previously reported by
Boucher et al. (2005). Furthermore, the increase in the cAMP
intracellular levels, induced by forskolin or phosphodiesterase
inhibitors, as well as the administration of a PKA activator
counteracts the EMT induced by TGF-β1 (Zhang et al., 2006a,b;
Nadella et al., 2008; Lambers et al., 2015). By contrast, other
evidence has been reported regarding the positive role of
cAMP and PKA in the induction of EMT (Shaikh et al.,
2012). Conversely, it has been widely accepted that ERK
phosphorylation is one of the mechanisms that promotes the
EMT program (Singh et al., 2017). In fact, ERK activation is
one of the Smad-independent events that is necessary for TGF-
β-mediated EMT (Gui et al., 2012; O’Connor and Gomez, 2014).
Therefore, in the present study, the effects of A2BAR
stimulation on EMT was investigated in human lung epithelial
cells. Particularly, the role of this adenosine receptor subtype
in directly modulating the epithelial-mesenchymal markers
under physiological or inflammatory conditions (TGF-β1) was
analyzed. Furthermore, the intracellular pathways activated by
A2BAR, cAMP/PKA, and MAPK/ERK, involved in EMT, were
explored.
MATERIALS AND METHODS
Material and Reagents
Human type II alveolar epithelial cells (A549, American
Type Culture Collection, CCL-195), were kindly provided
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by Dr. R. Danesi, University of Pisa, Pisa, Italy. The
chemicals 2-[6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)
phenyl]pyridin-2-ylsulfanyl] acetamide (BAY 60-6583) and N-
(4-acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-diprop-
yl-1H-purin-8-yl)phenoxy]-acetamide (MRS1706) were
purchased from Tocris Bioscience (Bristol, United Kingdom).
The RNeasy minikit was obtained from Qiagen. The Script cDNA
synthesis kit was furnished by Bio-Rad s.r.l. Fluocycle II SYBR
was from Euroclone (Milan, Italy). TGF-β1 was purchased from
Sigma–Aldrich. All other reagents were obtained from standard
commercial sources and were of the highest commercially
available grade
Cell Culture
Human type II alveolar epithelial cells (A549) were maintained in
DMEM-F12 containing 10% FBS, 2 mM L-glutamine, 100 U/ml
penicillin and 100 µg/ml streptomycin at 37◦C in a humidified
5% CO2 atmosphere. For the different experiments, cultures of
cells were maintained in serum-free DMEM for 8 h prior to
stimulation with cytokines or other reagents.
RNA Extraction and Real-Time RT-PCR
Analysis
A549 cells were untreated or treated with DMSO (CTRL) or
BAY 60-6583 (100 nM) in the absence or presence of TGF-β1
(10 ng/ml) and MRS 1706 (1 µM) for the indicated time. At
the end of treatments, cells were collected, and total RNA was
extracted using Rneasy R©Mini Kit (Qiagen, Hilden, Germany)
as previously reported (Da Pozzo et al., 2014); residual DNA
was removed using RNase free DNAse set (#79254, Qiagen,
Hilden, Germany). The RNA purity was checked measuring the
A260/280 ratio. cDNA synthesis was performed with 400 ng
of RNA using i-Script cDNA synthesis kit (BioRad, Hercules,
CA, United States) following manufacturer’s instructions. Real-
time RT-PCR reactions consisted of 25 µL Fluocycle R©II SYBR R©
(Euroclone, Milan, Italy), 1.0 µL of both 10 µM forward and
reverse primers, 2.5 µL cDNA (100 ng), and 20.5 µL of H2O.
All reactions were performed for 40 cycles using the following
temperature profiles: 98◦C for 30 s (initial denaturation); 55◦C
for 30 s (annealing); and 72◦C for 3 s (extension). The primer
sequences were listed in Table 1. When possible, the primers
used were designed to span intron/exon boundaries and the
β-actin was used as the housekeeping gene. The mRNA levels for
each sample were normalized against β-actin mRNA levels, and
the relative expression was calculated by using a Ct value. PCR
specificity was determined by both the melting curve analysis and
gel electrophoresis.
Western Blotting Analysis
A549 cells (3.5 × 104 cell/cm2) were maintained untreated or
treated with DMSO (CTRL) or BAY 60-6583 (100 nM) in the
absence or presence of TGF-β1 (10 ng/ml) and MRS 1706 (1 µM)
for 48 h. At the end 200 µl RIPA buffer were added for 60 min at
4◦C to lyse the cells. Fifty microgram of total proteins was diluted
in Laemmli solution, resolved by SDS-PAGE (7.5%), transferred
to PVDF membranes and probed overnight at 4◦C with primary
anti-A1AR (diluted 1:200, sc-28995; Santa Cruz Biotechnology),
anti-A2AAR (diluted 1:200, sc-13937; Santa Cruz Biotechno-
logy), anti-A2BAR (diluted 1:150, sc-28996; Santa Cruz
Biotechnology), anti-A3AR (diluted 1:200, sc-13938; Santa
Cruz Biotechnology), anti-E-cadherin antibody (diluted 1:200;
sc-7870; Santa Cruz Biotechnology), anti-N-cadherin antibody
(diluted 1:200; sc-7939; Santa Cruz Biotechnology) anti-
Vimentin (diluted 1:1000, #5741; Cell Signaling Technology)
or β-actin antibody (diluted 1:1000; MAB1501, Merck KGaA,
Darmstadt, Germany). The primary antibody was detected
using appropriate secondary antibody. The peroxidase was
detected using a chemiluminescent substrate (ECL, Perkin
Elmer), and the images were acquired by photographic
film or by LAS4010 (GE Health Care Europe, Uppsala,
Sweden). Immunoreactive bands were quantified performing
a densitometric analysis with Image J Software (version 1.41;
Bethesda, MD, United States).
Immunofluorescence Analysis
A549 cells were seeded at 3.5 × 104 cell/cm2 in chamber
slide (BD Biosciences, San Jose, CA, United States). After
treatment, cells were fixed in 2% paraformaldheyde in 0.1 M
phosphate buffer, washed three times with PBS, rinsed, and
blocked for 45 min with PBS containing 0.1% Triton-X 100
and 1% BSA. After washing, cells were incubated overnight
at 4◦C with mouse monoclonal anti-β-actin antibody (diluted
1:500; MAB1501, Merck KGaA, Darmstadt, Germany) or a rabbit
polyclonal anti-A2BAR (diluted 1:100, sc-28996; Santa Cruz
Biotechnology) primary antibodies diluted in PBS containing
0.03% Triton-X 100 and 1% BSA overnight at 4◦C. After washing,
to visualize the staining, cells were incubated with Alexa Fluor
488- and Alexa Fluor 568-labeled goat anti-mouse (1:500) or
anti-rabbit (1:500) antibodies for 2 h at room temperature.
Then slides were covered with Vectashield conjugated with
DAPI (Vector Laboratories, Burlingame, CA, United States).
Images were obtained with a Nikon Ni-E microscope, using
a 20× objective with 1.45 NA and a recommended pinhole
size of less than 1.0 mm, and equipped with digital camera
Nikon Mod.DS-Ri2. The images were processed with ImageJ
software.
Cell Viability Assay
A549 cells were seeded at a density of 3 × 103 cells/well
in a black, clear bottom PerkinElmer 96-well CellCarrierTM
microplate (#6005550). After 24 h, the cells were starved for
8 h with non-complete medium; then, cells were treated with
different concentrations of BAY 60-6583 (0.5 nM–1 µM) or TGF-
β1 (5–20 ng/ml) alone or in combination for 48 or 72 h. Following
the treatment period, cells were imaged with the EnSightTM
multimode plate reader equipped with well-imaging module,
and Kaleido Data Acquisition and Analysis Software. Brightfield
images were taken before and 48 or 72 h after treatments to
allow for a Cell Count comparison between both time points.
The cell count was determined using the pre-defined Brightfield
Cell Count algorithm provided by the Kaleido software. Cell with
a mean area ≥100 µm2 were counted. Data were normalized
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TABLE 1 | Primers used for real-time RT-PCR.
Gene Primer nucleotide sequences Product size (base pairs) Annealing temperature
ADORA1 FOR: 5′-TCCCTCTCCGGTACAAGATG -3′
REV: 5′-GCTGCTTGCGGATTAGGTAG-3′
300 bp 55◦C
ADORA2A FOR: 5′-TCTTCAGTCTCCTGGCCATC-3′
REV: 5′-TCCAACCTAGCATGGGAGTC-3′
156 bp 55◦C
ADORA2B FOR: 5′-TCCATCTTCAGCCTTCTGGC -3′
REV: 5′-AAAGGCAAGGACCCAGAGGA-3′
129 bp 55◦C
ADORA3 FOR: 5′-CAGCAAAGCGTCAACTCGTGC -3′
REV: 5′-CAAACGGGAGAAGCAGAGGAAC-3′
118 bp 55◦C
CDH1 FOR: 5′-AGGGGTTAAGCACAACAGCA-3′
REV: 5′-GGGGGCTTCATTCACATCCA-3′’
395 bp 55◦C
Vimentin FOR: 5′-CTCTTCCAAACTTTTCCTCCC-3′
REV: 5′-AGTTTCGTTGATAACCTGTCC-3′
134 bp 55◦C
CDH2 FOR: 5′-AGGGGACCTTTTCCTCAAGA-3′
REV: 5′-CAATGTCAATGGGGTTCTCC-3′
246 bp 55◦C
ZEB1 FOR: 5′-CCCTTGAAAGTGATCCAGCCA-3′
REV: 5′-AGACCCAGAGTGTGAGAAGCG-3′
354 bp 55◦C
Snail FOR: 5′-AAGATGCACATCCGAAGCCA-3′
REV: 5′-CATTCGGGAGAAGGTCCGAG-3′
237 bp 55◦C
Slug FOR: 5′-TGGTTGCTTCAAGGACACAT-3′
REV: 5′-GTTGCAGTGAGGGCAAGAA-3′
66 bp 55◦C
TWIST FOR: 5′-ACGAGCTGGACTCCAAGATG-3′
REV: 5′-CACGCCCTGTTTCTTTGAAT-3′
290 bp 55◦C
β-actin FOR: 5′-GCACTCTTCCAGCCTTCCTTCC-3′
REV: 5′-GAGCCGCCGATCCACACG-3′
254 bp 55◦C
to the cell count at t0 and expressed as the number of cell per
well.
cAMP Quantification
A549 cells were seeded at a density of 3 × 103 cells/well
in a black, clear bottom PerkinElmer 96-well CellCarrierTM
microplate (#6005550). After 24 h, the cells were starved for
8 h with non-complete medium; then, cells were treated with
different concentrations of BAY 60-6583 (0.1 nM–1 µM) in
the absence or presence of TGF-β1 (10 ng/ml) in 100 µl
of non-complete medium for 48 h. Cells were imaged with
the EnSightTM multimode plate reader. The desensitization
experiments were performed incubating the cells with BAY
60-6583 (100 nM) in the presence or absence of TGF-β1
(10 ng/ml) for 48 h. At the end the medium was changed
and cells were treated with different concentrations of BAY 60-
6583 (0.1 nM–1 µM) for 15 min. Then, cells were lysed with
50 µl of 1X lysis buffer (PerkinElmer, #AL003C) supplemented
with protease inhibitors and phosphatase inhibitors for 10 min
with gentle shaking. Lysates were either tested immediately in
AlphaLISA assays or frozen at –80◦C for later testing. cAMP
levels were quantified using cAMP AlphaLISA kit (PerkinElmer,
#AL312) following manufacturer’s instructions. Standard curves
for each AlphaLISA immunoassay were performed in the same
diluent as the samples being tested (1X lysis buffer with
supplements) using the recombinant standards provided in each
kit. Curves were plotted with a sigmoidal concentration-response
curve with variable slope. Quantitation of protein levels in
cellular assays were interpolated off their respective standard
curves.
MAPK (Mitogen-Activated
Phosphorylation Kinase) Assays
A549 cells were seeded at a density of 3 × 103 cells/well in 96
multi-well plate. After 24 h, the cells were starved for 8 h with
non-complete medium; then, cells were treated with BAY 60-
6583 (100 nM) in the absence or presence of TGF-β1 (10 ng/ml)
and MRS1706 (1 µM) for 5 min, 30 min, 6, 24, and 48 h.
In some experiments, before incubation with BAY 60-6583 or
TGF-β1, cells were pre-treated for 30 min with PD98059 (1 µM)
(MEK, inhibitor). At the end of treatments, cells were fixed
with 4% formaldehyde to preserve activation of specific protein
modification. Levels of total and phosphorylated extracellular
signal-regulated kinases (ERK1/2) were determined by ELISA
assays, as previously reported (Giacomelli et al., 2015). Briefly,
the cells were washed three times with wash buffer (0.1% Triton
X-100 in PBS) and 100 µl of quenching buffer (1% H2O2; 0.1%
sodium azide in wash buffer) was added and incubation was
protracted for other 20 min. The cells were washed with PBS
twice, and then 100 µl of blocking solution (1% BSA; 0.1%
Triton X-100 in PBS) was added for 60 min. After blocking,
cells were washed three times with wash buffer and the specific
primary antibodies (anti-phospho ERK1/2, 1:500, sc-7383 Santa
Cruz Biotechnology; anti-ERK1/2, 1:500, #4695 Cell Signaling
Technology) were added on at 4◦C. Subsequent incubation with
secondary HRP-conjugated antibodies and developing solution
allowed a colorimetric quantification of total and phosphorylated
levels. Blanks were obtained by treating cells in the absence of the
primary antibody. The relative number of cells in each well was
then determined using Crystal Violet solution. The results were
calculated by subtracting the mean background from the values
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obtained from each test condition; values were normalized to the
number of cells in each well, and were expressed as the percentage
of untreated cells (basal).
Quantification of E-cad and N-cad
Proteins
A549 cells were seeded at a density of 3× 103 cells/well in a black,
clear bottom PerkinElmer 96-well CellCarrierTM microplate
(#6005550). After 24 h, the cells were starved for 8 h with
non-complete medium; then, cells were treated with different
concentrations of BAY 60-6583 (0.1 nM–1 µM) in the absence
or presence of TGF-β1 (10 ng/ml) in 100 µl of non-complete
medium for 48 h. In some experiments, before incubation with
BAY 60-6583 or TGF-β1, cells were pre-treated for 30 min with
PD98059 (1 µM, MEK, inhibitor), H89 (100 nM, PKA inhibitor)
or 8-Br-cAMP (100 nM–1 µM, cAMP analog & PKA activator).
Then, cells were imaged with the EnSightTM multimode plate
reader. After imaging, cells were lysed with 50 µl of 1X lysis
buffer (PerkinElmer, #AL003C) supplemented with protease
inhibitors and phosphatase inhibitors for 10 min with gentle
shaking. E-cad were quantified using E-cadherin AlphaLISA
kit (PerkinElmer, #AL370), and N-cad were quantified using
N-cadherin AlphaLISA kit (PerkinElmer, #AL379) following the
manufacturer’s instructions. Standard curves for each AlphaLISA
immunoassay were performed in the same diluents as the
samples being tested (1X lysis buffer with supplements), using
the recombinant standards provided in each kit. Curves were
plotted with a sigmoidal concentration-response curve with
variable slope. Quantitation of protein levels in cellular assays
were interpolated off their respective standard curves.
Statistical Analysis
The Graph-Pad Prism program (GraphPad Software Inc.,
San Diego, CA, United States) was used for data analysis and
graphic presentation. All data are the mean± SEM of at least
three different experiments. Statistical analysis was performed by
one-way analysis of variance (ANOVA) with Dunnett post hoc
analysis to compare the data to the control, or two-way ANOVA
with Bonferroni correction and two-sided tests for multiple
comparisons. EC50 values were reported as mean of the values
obtained in at least three independent experiments performed in
duplicate± SEM. P≤ 0.05 was considered statistically significant.
RESULTS
Adenosine Receptor Expression in
Human Epithelial Lung Cells and Its
Modulation by TGF-β1
The A549 human alveolar epithelial cells have been widely used to
study the fibrotic process in the lung and related EMT mechanism
(Kim et al., 2007; Ji et al., 2016). Furthermore, these cells were
maintained in serum-free medium to increase the epithelial
phenotype (Dong et al., 2014).
First, the expression of the AR subtypes in A549 cells was
evaluated after incubation in serum-free medium for 48 h
(Figure 1A). All the ARs were expressed under this condition,
and the A2BAR subtype was the most expressed with a fold
change of approximately 200 (Figure 1A).
TGF-β1 has been reported to affect the expression of several
proteins (Zhang, 2017); thus, the effects of cytokine treatment on
AR expression were evaluated (Figures 1B–D). Challenging
the A549 cells for 48 h with increasing concentrations
of TGF-β1 (5–20 ng/ml) modified the expression of the
different adenosine subtypes. Particularly, A1AR expression
was significantly increased when a high concentration of
TGF-β1 was used; conversely, A2A and A3 receptor expression
was slightly decreased when increased concentration of
the cytokine was applied. Regarding A2BAR expression,
low concentrations of TGF-β1 (5 or 10 ng/ml) were not
sufficient to modify the receptor expression; by contrast, a
higher concentration of the cytokine significantly decreased
its expression. In this light, further experiments were
performed using a maximum concentration of the cytokine
of 10 ng/ml for 48 h to minimize the change in the receptor
expression.
TGF-β1 Effects on A2BAR Functionality
and Lung Cell Growth
A2BAR stimulation or blockade has been correlated to different
levels of cell proliferation depending on the cell type and
culture condition (Phosri et al., 2017; Zhou et al., 2017). Thus,
the effects of A2BAR stimulation in the absence or presence
of TGF-β1 were evaluated in the lung cells (Figure 2). The
selective agonist BAY 60-6583 was used to stimulate selectively
the A2BAR subtype. The compound could slightly increase the
cell proliferation when used at low concentration (50–100 nM)
for 48 or 72 h treatment (Figure 2A), conversely, it produced
a decrease in proliferation when used at a high concentration
(1 µM), with a significant effect after 72 h of treatment
(13970 ± 488 n◦ of cells CTRL, 11038 ± 816 n◦ of cells BAY;
P ≤ 0.05). TGF-β1 alone presented a hormetic concentration-
response course: the lower concentration possessed positive
effects on cell proliferation that are lost at higher concentrations
(Figure 2B). The combined treatment with BAY 60-6583 and
TGF-β1 for 48 h did not significantly affect the cell proliferation
(Figure 2C). These data confirmed the diverse role of A2BAR in
the cell proliferative mechanism. Based on such results, further
experiments were then performed using BAY 60-6583 at a
concentration (100 nM) not affecting significantly the A549 cell
proliferation.
Next, the effect of cytokine treatment on A2BAR functionality
was evaluated by measuring the agonist-mediated cAMP
production (Figure 2D). The potency of BAY 60-6583 was in the
nanomolar range (EC50 = 17.2 ± 2.5 nM), as derived by agonist
concentration-response curves, it is a value comparable to that
described for the same agonist in transfected cells (Figure 2D)
(Trincavelli et al., 2014). The presence of TGF-β1 did not
significantly affect the agonist potency (EC50 = 10.0 ± 1.8 nM),
even if the maximal effect of BAY in the production of
cAMP was slightly increased (Emax = 4.3 pmol – TGF-β1;
Emax = 5.8 pmol+TGF-β1, P = 0.0565) even if it was
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FIGURE 1 | Expression of ARs in A549 cells and their modulation in the presence of TGF-β1. (A) A549 cells were maintained in serum-free medium for 48 h. Next,
real-time RT-PCR analysis of A1, A2A, A2B, and A3 adenosine receptors was performed. The data were expressed as the fold change vs. A1AR expression, which
was set to 1 and are the mean values±SEM of three different experiments. (B,C) A549 cells were treated with different concentrations of TGF-β1 for 48 h, and the
levels of AR subtypes were evaluated by Western blotting. One representative Western blot is presented (C). The bar graph (D) shows the densitometric analysis of
the Western blot performed using the ImageJ program. Cells were maintained in serum-free medium for 48 h in the absence (a) or presence (b) of TGF-β1. Next,
cells were fixed and stained with anti-β actin and visualized with goat anti-rabbit Alexa Fluor 568 (red). Nuclei were counterstained with DAPI (blue). The data are
presented as the means of three different experiments. The significance of the differences was determined by one-way ANOVA, followed by Dunnett’s post hoc test:
∗P ≤ 0.05, ∗∗∗P ≤ 0.001 vs. the CTRL.
not statistically significant. These results are in accordance
with the effect of other cytokines on A2BAR functionality
(Daniele et al., 2017); in fact, TNF-α has been demonstrated
to increase A2BAR coupling to the Gs protein (Daniele et al.,
2017).
In parallel, the BAY-induced ERK phosphorylation was
evaluated in order to further assess the A2BAR functionality
(Figure 2E). The agonist was able to produce a concentration-
dependent increase of pERK with a potency in the sub-
micromolar range of (EC50 = 114.8± 24.5 nM).
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FIGURE 2 | Effects of BAY 60-6583 and TGF-β1 on cell proliferation and cAMP accumulation. A549 cells were treated in serum-free medium with different
concentrations of BAY 60-6583 (0.5 nM–1 µM) and TGF-β1 (5–20 ng/ml), alone or in combination, for 48 h (A–C). At the end of the treatments, the cell numbers
were counted. The data were expressed as cell number per well, and they were presented as the mean values±SEM of three independent experiments, each
performed in duplicate. The significance of the differences was determined by one-way ANOVA, followed by Dunnett’s post hoc test: ∗P ≤ 0.05 vs. the CTRL.
(D) A549 cells were maintained in the absence or presence of TGF-β1 (10 ng/ml) for 48 h. Next, cells were challenged with increasing concentrations of BAY
60-6583, and cAMP production was quantified. (E) A549 cells were treated with different concentrations of BAY 60-6583 for 5 min and the levels of pERK were
quantified. The data were expressed as pmol of cAMP and are the mean values±SEM of three independent experiments, each performed in duplicate.
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Effects of A2BAR Stimulation on EMT
Markers in the Absence or Presence of
TGF-β1
Typically, the EMT process is triggered and maintained by
the action of different cytokines and extracellular stimuli that,
through the activation of specific intracellular pathways, modify
the expression of several proteins (Nieto et al., 2016). A549 cells
were treated for 48 h with the A2BAR agonist alone or in the
presence of TGF-β1 (10 ng/ml), which has been reported to
induce EMT (Kawata et al., 2012). First, a morphological analysis
of the cells was performed (Figures 3A,B). TGF-β1 treatment
induced a change in cell morphology: most of the A549 cells,
which normally display an oval shape, showed an elongated shape
with a fibroblast-like appearance. Surprisingly, cells challenged
with the A2BAR agonist lead to a partial morphological change,
with only some cells presenting an elongated shape, suggesting
the induction of partial EMT.
The morphological changes, which are characteristic of cells
undergoing EMT, are accompanied by a shift in the expression of
epithelial genes to a mesenchymal gene repertoire (Nieto et al.,
2016). Accordingly, challenging cells with TGF-β1 modified the
expression of EMT markers, leading to a significant increase
in the expression of the mesenchymal markers, Vimentin and
N-cadherin (128.8± 6.5, P≤ 0.01, and 162.7± 3.8% P≤ 0.001 vs.
CTRL, respectively; Figures 3C,D) and a concomitant decrease
in the expression of the epithelial marker E-cadherin (6.7± 2.5%
P ≤ 0.001 vs. CTRL; Figures 3C,D). The data were confirmed
at the gene expression level by real-time RT-PCR analysis
of E-cadherin (CDH1), Vimentin, and N-cadherin (CHD2)
expression (Figure 3E).
A2BAR stimulation was able to slightly decrease the expression
of E-cad protein (Figures 3C,D) and increase the expression of a
mesenchymal marker (N-cad, 119.8± 0.6% vs. CTRL; P ≤ 0.05).
These effects are in accordance with the effects elicited by
BAY on epithelial/mesenchymal gene transcription. Conversely,
A2BAR activation in the presence of TGF-β1 produced
an opposite effect, significantly counteracting the induced
EMT (Figures 3C–E). These effects were almost completely
counteracted by concomitant treatment with the A2BAR selective
inverse agonist MRS 1706 (1 µM), demonstrating that they
were mediated specifically by A2BAR. The treatment with
MRS 1706 alone was not able to significantly modify the
expression of mesenchymal and epithelial markers in the absence
or presence of TGF-β1 demonstrating that the adenosine in
the medium was not sufficient to induce a basal A2BAR
activation.
Effects of A2BAR Modulation on EMT
Major Transcription Factors (EMT-TFs)
The modulation of classical EMT centers on the transcriptional
control of different transcription factors: Snail (SNAI1), Slug
(SNAI2), ZEB1 and TWIST (Nieto et al., 2016). To gain
insight into the mechanisms by which A2BAR affects E-cadherin
deficiency alone and in TGF-β1-induced A549 cells, the
expression levels of the EMT-TFs were examined using real-time
RT-qPCR (Figure 4).
A549 cells expressed Snail and Slug at low levels
(Supplementary Figure 1), in accordance with the high
expression of E-cad (Figure 2). Treatment with TGF-β1 for 48 h
changed the expression pattern of these genes (Figure 4A), with
a significant increase in ZEB1 (1.57 ± 0.13-fold; P ≤ 0.05), Slug
(2.63 ± 0.25-fold; P ≤ 0.001), in accordance with the literature
data (Ji et al., 2016). Next, the effects of A2BAR stimulation
(BAY 60-6583) or blockade (MRS 1706) were evaluated
(Figure 4B). The MRS alone could not modify the expression
of EMT-TFs, highlighting that the endogenous activation of
the receptor was not sufficient to modify the related-EMT gene
expression. Conversely, A2BAR activation modified the gene
repertoire, producing a significant increase in the Slug expression
(1.65 ± 0.16-fold; P ≤ 0.05). These data are in accordance
with the effects of A2BAR activation on epithelial/mesenchymal
markers (Figure 3).
Next, the role of A2BAR stimulation on EMT-TF was
evaluated in the presence of TGF-β1 (Figure 4C). As expected,
the A2BAR activation counteracted the effects of cytokine
treatment, with a significant decrease in ZEB1 and Slug
expression. When the A2BAR inverse agonist was applied, the
TGF-β1-induced decrease in gene expression was completely
counteracted, demonstrating that these effects were mediated
by A2BAR.
The Balance of cAMP Production and
MAPK/ERK Activation Orchestrates the
A2BAR Effects on EMT
A2BAR couples to Gαs proteins, leading to an increase
in intracellular cAMP, and to the Gq-PLC pathway, which
induces the activation of the MAPK/ERK pathway (Schulte
and Fredholm, 2003; Sun and Huang, 2016). Thus, activation
of these two intracellular signaling pathways were investigated
following A2BAR stimulation, in the absence or presence of TGF-
β1 (Figure 5). MRS 1706 alone did not affect the activation
of the two pathways, demonstrating that the adenosine levels
in our cellular model were not sufficient to activate the
receptor. BAY was able to increase the intracellular cAMP
concentration (Figure 5A), and significantly enhance ERK1/2
phosphorylation (178.9± 10.5% vs. CTRL, P ≤ 0.05; Figure 5B),
producing transient activation of these kinases (Figure 5C). The
effects evoked by A2BAR stimulation were almost completely
reversed by the A2BAR inverse agonist MRS1706, demonstrating
the specific involvement of the A2BAR subtype. As expected,
TGF-β1 did not produce a significant increase in the cAMP
levels (Figure 5A); conversely, it was able to significantly
increase ERK1/2 phosphorylation (341.7 ± 16.2% vs. CTRL,
P ≤ 0.001; Figure 5B). Both BAY and TGF-β1 induced transient
activation of ERK1/2 but with different kinetics; whereas ERK
phosphorylation induced by BAY peaked within 30 min and then
returned to the basal value within 6 h, TGF-β1 caused a more
sustained ERK activation up to 48 h of cell treatment (48 h,
155.2 ± 7.8%, TGF-β1; 85.3 ± 8.8%, BAY; P ≤ 0.05; Figure 5C).
These data highlighted a difference in the final reorganization
of the intracellular pathways activated by the cytokine and the
receptor.
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FIGURE 3 | A2BAR stimulation affects EMT markers and decreases TGF-β1-induced EMT. A549 cells were treated with BAY 60-6583 (100 nM) in the absence or
presence of TGF-β1 (10 ng/ml) for 48 h. When indicated, the A2BAR inverse agonist, MRS 1706 (1 µM), was applied. (A) At the end of the incubation times,
representative images were taken. Scale bar = 100 µm. (B) Cells treated as above were fixed and stained with anti-β actin and visualized with goat anti-mouse
AlexaFluo 488 (green). Nuclei were counterstained with DAPI (blue). (C,D) A549 cells were treated as described above, and the levels of the EMT markers E-cad,
Vimentin and N-cad were evaluated by Western blotting. One representative Western Blot is presented (C). The bar graph (D) shows the densitometric analysis of
the Western blot performed using the ImageJ program. The data are presented as the means of three different experiments. (E) Real-time RT-PCR analysis of the
same EMT markers were performed. The data were expressed as the fold change vs. the CTRL levels, which were set to 1 and are the mean values±SEM of three
different experiments each performed in duplicate. The significance of the differences was determined by one-way ANOVA, followed by Dunnett’s post hoc test or
two-way ANOVA with Bonferroni correction and two-sided tests for multiple comparisons. ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001 vs. the CTRL; #P ≤ 0.05,
###P ≤ 0.001 vs. TGF-β1 alone; ◦◦P ≤ 0.01 vs. TGF-β1 + BAY.
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FIGURE 4 | A2BAR activation of EMT transcription factors. (A) A549 cells were treated with TGF-β1 (10 ng/ml) for 48 h. At the end of the incubation, real-time
RT-PCR analysis of the transcription factors that act as master regulators of EMT (ZEB1, Snail, Slug, TWIST) was performed. (B,C) A549 cells were treated with BAY
60-6583 (100 nM) in the absence or presence of TGF-β1 (10 ng/ml) for 48 h. When indicated, the A2BAR inverse agonist MRS 1706 (1 µM) was applied. At the end
of the incubation, real-time RT-PCR analysis of the transcription factors that act as master regulators of EMT (ZEB1, Snail, Slug, TWIST) was performed. The data
were expressed as the fold change vs. the CTRL levels, which were set to 1 and are the mean values±SEM of three different experiments, each performed in
duplicate. The significance of the differences was determined by one-way ANOVA, followed by Bonferroni’s post hoc test or two-way ANOVA with Bonferroni
correction and two-sided tests for multiple comparisons. ∗P ≤ 0.05, ∗∗∗P ≤ 0.001 vs. the CTRL; #P ≤ 0.05, ##P ≤ 0.01 vs. TGF-β1 alone; § P ≤ 0.05 vs. the
TGF-β1 + BAY.
When A2BAR was activated in the presence of TGF-β1,
the receptor activation produced a significant increase in the
intracellular cAMP concentration (56.4 ± 1.9 nM, CTRL;
96.6 ± 5.3 nM, TGF-β1+BAY P ≤ 0.01; Figure 5A). This effect
was in accordance with the slight increase in A2BAR functionality
that was noticed in the presence of the cytokine (Figure 2D).
Regarding pERK1/2, the co-treatment led to a modest decrease
in phosphorylation. The BAY activities on cAMP and pERK1/2
were most completely counteracted by cell pre-incubation with
the A2BAR inverse agonist MRS1706. Finally, TGF-β1 and BAY
did not affect the amount of total ERK (Supplementary Figure 2).
To elucidate if the different activation of cAMP and ERK
pathway in the presence of the cytokine, could be related
to A2BAR desensitization, the functionality of the receptor
was evaluated after 48 h of cell treatment in the absence
or presence of BAY and TGF-β1 alone or in combination
(Figure 5D). In the basal condition (48 h without treatment),
A2BAR maintained its functional response. The cell treatment
with BAY (100 nM) for 48 h induced the desensitization of the
A2B receptor (219.9 ± 7.7% in Basal condition; 113.3 ± 13.6%
in BAY pre-treated cells; P ≤ 0.001). Cytokine alone was not
able to significantly interfere on the receptor desensitization.
Interestingly, when cells were treated with BAY in the presence of
TGF-β1 for 48 h, the desensitization of the receptor was partially
impaired (164.2± 8.7%; P ≤ 0.01).
cAMP/PKA Regulation of EMT Markers
in Human Epithelial Cells
The role of the cAMP pathway in EMT is controversial,
depending on the cell type, the nature of the EMT inducers
and maximum levels of the intracellular cAMP obtained (Weng
et al., 2015). Thus, the effects of different levels of cAMP
on EMT markers in our cellular model were investigated
using the cAMP analog Br-cAMP (8-bromoadenosine 3′,5′-cyclic
monophosphate) as the PKA activator (Figure 6). Br-cAMP
(100 nm–1 µM) induced a concentration-dependent increase in
the intracellular cAMP levels (Figure 6A). Surprisingly, different
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FIGURE 5 | Effects of BAY 60-6583 and TGF-β1 on cAMP accumulation and ERK 1/2 phosphorylation. (A) A549 cells were treated with BAY 60-6583 (100 nM) in
the absence or presence of TGF-β1 (10 ng/ml) for 48 h. When indicated, the A2BAR inverse agonist, MRS 1706 (1 µM), was applied. At the end of the treatment, the
cAMP production was quantified. The data were expressed as cAMP concentrations and were presented as mean values±SEM of three independent experiments,
each performed in duplicate. (B,C) Cells treated as above for different time (30 min-48 h), were fixed, and ERK 1/2 phosphorylation was measured by
immunoenzymatic assay. (B) ERK 1/2 phosphorylation after 30 min of treatment. (C) Time-course of ERK 1/2 phosphorylation in A549 cells. The data were
expressed as the percentage versus untreated cells (CTRL) set to 100%±SEM of at least three different experiments performed in duplicate. ∗P ≤ 0.05, ∗∗P ≤ 0.01,
∗∗∗P ≤ 0.001 vs. the CTRL; #P ≤ 0.05 vs. TGF-β1 alone; § P ≤ 0.05 vs. the TGF-β1 + BAY. (D) Cells were treated with BAY 60-6583 (100 nM) in the absence or
presence of TGF-β1 (10 ng/ml) for 48 h. After extensive washing, cells were treated for 15 min with different concentrations of BAY60-6583. Next, intracellular cAMP
levels were evaluated. The data were expressed as the percentage versus untreated cells (CTRL-Basal) set to 100%±SEM of at least three different experiments
performed in duplicate. ∗P ≤ 0.05, ∗∗∗P ≤ 0.001 vs. the CTRL-Basal; #P ≤ 0.05, ###P ≤ 0.001 vs. respective basal condition. The significance of the differences was
determined by one-way ANOVA, followed by Dunnett’s post hoc test or two-way ANOVA with Bonferroni correction and two-sided tests for multiple comparisons.
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FIGURE 6 | Effect of the cAMP pathway on E-cadherin and N-cadherin expression. A549 cells were treated with Br-cAMP (100 nm–1 µM) in the absence or
presence of TGF-β1 (10 ng/ml) for 48 h. (A) At the end of the treatment, cAMP production was quantified. The data were expressed as cAMP concentrations and
are presented as mean values±SEM of three independent experiments, each performed in duplicate. Cells treated as above were lysed, and the expression of
E-cadherin (B) or N-cadherin (C) was quantified using AlphaLISA kits. The data were expressed as E-cadherin and N-cadherin concentrations (ng/ml) and are
presented as mean values±SEM of three independent experiments, each performed in duplicate. The significance of the differences was determined by two-way
ANOVA with Bonferroni correction and two-sided tests for multiple comparisons. ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001 vs. the CTRL; #P ≤ 0.05, ##P ≤ 0.01, vs.
TGF-β1 alone.
concentrations of the activator caused opposite effects on E-cad
(Figure 6B) and N-cad (Figure 6C) expression. A high Br-cAMP
concentration increased E-cad and decreased N-cad expression.
A low Br-cAMP concentration (100 nM) was sufficient to
determine a modest decrease of E-cad (1646 ± 56 ng/ml, CTRL;
1540± 93 ng/ml, Br-cAMP; Figure 6B) and an increase of N-cad
(246 ± 35 ng/ml, CTRL; 270 ± 8 ng/ml, Br-cAMP; Figure 6C)
even if these variations were not statistically significant. When
TGF-β1 and BAY were used simultaneously, the activator
produced higher cAMP levels and a concentration-dependent
increase in E-cad and decrease in N-cad.
These data demonstrate that, in our cellular model, when
the cAMP was increased up to high concentrations, it could
negatively affect the EMT process. Conversely, when cAMP levels
remained low, it seems to mediate the opposite effects, promoting
a slight decrease in epithelial markers and an increase in the
mesenchymal markers. This controversial nature of the cAMP
analogue on the EMT process is in accordance with the recent
data reported by Zuccarini et al. (2017).
The cAMP/PKA-MAPK/ERK Balance in
the A2BAR Modulation of EMT Markers
and EMT-TFs
Nevertheless, high levels of cAMP counteract EMT, and
ERK phosphorylation mediated by MAPK activation has been
demonstrated to promote EMT (Singh et al., 2017). Thus, the
ability of A2BAR to modify the amounts of both pERK and of
cAMP could be a possible mechanism by which the receptor
agonist affects epithelial/mesenchymal markers. In this respect,
the involvement of A2BAR in the regulation of EMT markers
and transcription factors was investigated in the presence of
PKA inhibitor (H89, 100 nM) and a mitogen-activated protein
kinase inhibitor (PD98059, 1 µM) (Figure 7, Supplementary
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FIGURE 7 | Effect of cAMP and ERK1/2 phosphorylation blockade on A2BAR-mediated changes in EMT markers. A549 cells were treated with BAY 60-6583
(100 nM) in the absence or presence of MRS 1706 (1 µM), PKA inhibitor H89 (100 nM) or MEK1/2 inhibitor PD98059 (1 µM) for 48 h. When indicated, the
antagonist and inhibitor were applied 30 min before treatment with BAY 60-6583. (A) At the end of the treatment, cAMP production was quantified. The data were
expressed as cAMP concentrations and are the mean values±SEM of three independent experiments, each performed in duplicate. (B) Cells were treated as above
(Continued)
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FIGURE 7 | Continued
and ERK 1/2 phosphorylation was evaluated after 30 min of treatment. The data were expressed as the percentage versus untreated cells (CTRL) set to
100%±SEM of at least three different experiments performed in duplicate. Cells treated as above were lysed, and the expression of E-cadherin (C) or N-cadherin
(D) were quantified using AlphaLISA kits. The data were expressed as E-cadherin and N-cadherin concentrations (ng/ml) and are the mean values±SEM of three
independent experiments, each performed in duplicate. The significance of the differences was determined by one-way ANOVA, followed by Dunnett’s post hoc test
or two-way ANOVA with Bonferroni correction and two-sided tests for multiple comparisons. ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001 vs. the CTRL; #P ≤ 0.05,
##P ≤ 0.01, ###P ≤ 0.001 vs. BAY alone. (E,F) Cells were treated as above and real-time RT-PCR analysis of EMT markers (E-cad, N-cad and Vimentin) (E), and
EMT transcription factors (ZEB1, Snail, Slug, TWIST) (F) was performed. The data were expressed as the fold change vs. the CTRL levels, which were set to 1 and
are the mean values±SEM of three different experiments each performed in duplicate. The significance of the differences was determined by one-way ANOVA,
followed by Dunnett’s post hoc test or two-way ANOVA with Bonferroni correction and two-sided tests for multiple comparisons. ∗P ≤ 0.05, ∗∗P ≤ 0.01,
∗∗∗P ≤ 0.001 vs. the CTRL; #P ≤ 0.05, ##P ≤ 0.01 vs. BAY alone.
Figure 3). The BAY-mediated increase in the intracellular cAMP
levels was not affected by H89 treatment (Figure 7A); conversely,
PD98059 was able to block BAY-mediated ERK phosphorylation
(Figure 7B). In this respect, the inhibitors were used to unveil the
involvement of the two signaling pathways in A2BAR mediated
triggering of EMT.
BAY decreased the protein density of E-cad and increased
that of the N-cad one; these effects were lost in the presence
of the inverse agonist MRS 1706, in accordance with the
abovementioned data (Figure 3). The ability of BAY to decrease
the expression of E-cad was augmented by pretreatment with
the PKA inhibitor (2718 ± 58 ng/ml, CTRL; 2045 ± 157 ng/ml,
BAY; P ≤ 0.01; 1483 ± 122 ng/ml, BAY+H89; P ≤ 0.001
vs. CTRL, P ≤ 0.01 vs BAY, Figure 7C). Similarly, A2BAR
mediated increase in N-cad was enhanced when the cAMP/PKA
axis was abrogated (239 ± 20 ng/ml, CTRL; 406 ± 29 ng/ml,
BAY; P ≤ 0.05; 558 ± 72 ng/ml, BAY+H89; P ≤ 0.001 vs.
CTRL, P ≤ 0.05 vs BAY; Figure 7D). These effects highlighted
that cAMP, through PKA activation, could partially antagonize
A2BAR-mediated EMT induction. When the MEK inhibitor
was used, the changes induced by A2BAR stimulation were
almost completely counteracted, restoring the basal conditions
(E-cad, 2586 ± 90 ng/ml, BAY+PD98059; P ≤ 0.05 vs BAY;
N-cad, 260 ± 49 ng/ml, BAY+PD89059; P ≤ 0.05 vs BAY,
Figures 7C,D). These results are in accordance with the effects
of the inhibitor treatments on A2BAR-mediated alteration of the
expression of CDH1, CDH2 and vimentin genes (Figure 7E).
Finally, the modulation of the EMT-TF gene expression
by BAY was evaluated in the presence of H89 and PD98059.
Similarly, regarding the EMT markers, the PKA inhibitor
slightly exacerbated the A2BAR-mediated effects; conversely,
the MEK inhibitor counteracted the BAY-mediated increase in
gene expression. The PD98059 activity was more pronounced
on Slug expression, causing a significant decrease of gene
expression (1.65 ± 0.16-fold, BAY; 1.61 ± 0.20-fold, BAY+H89;
0.93 ± 0.09-fold vs. CTRL, BAY+PD98059; P ≤ 0.05).
These data are consistent with the reported role of ERK
phosphorylation in the induction of Slug expression (Choi et al.,
2007; Joannes et al., 2014).
DISCUSSION
Adenosine receptors (ARs) have attracted great attention as
possible targets to control the EMT process in pathologies such
as fibrosis and cancer (Lu and Insel, 2014). However, among the
AR subtypes, no data have been reported that correlate A2BAR
activation with EMT in epithelial cells. In this respect, herein, we
report for the first time the ability of A2BAR activation to promote
EMT or contrast the effects of the extracellular inducer, TGF-
β1, in human lung epithelial cells. Furthermore, the ability of the
receptor activation to modulate two signaling pathways involved
in EMT, cAMP/PKA, and MAPK/ERK, was demonstrated as a
possible mechanism explaining the different effects mediated by
A2BAR stimulation in different extracellular microenvironment
(Figure 8).
Human carcinoma epithelial lung cells (A549) were
maintained under serum deprivation, a condition that has
been demonstrated to amplify the epithelial phenotype (Dong
et al., 2014). Although all the ARs are expressed in epithelial
lung cells, the A2B receptor subtype was demonstrated to be the
most represented, as previously reported (Roman et al., 2006).
Challenging these cells with TGF-β1 produced a marked change
in the phenotype through the simultaneous decrease in epithelial
markers (E-cad) and increase in mesenchymal markers (N-cad).
In accordance with the literature (Kawata et al., 2012), these data
demonstrated the suitability of the model to study the A2BAR
involvement in the EMT process.
A2BAR stimulation modified the expression of
epithelial/mesenchymal markers with a low but significant
amplitude. Surprisingly, the same receptor could counteract the
EMT induction mediated by TGF-β1. These opposite effects
elicited by A2BAR stimulation in lung cells reflect the well
documented debated role of this receptor in the onset and
progression of different pathologies. The receptor activation
has been reported to protect the lungs and other tissues from
inflammation and acute injury (Eckle et al., 2008; Davies et al.,
2014; Hoegl et al., 2015). By contrast, other evidence has been
reported concerning the A2BAR-mediated pro-fibrotic effects and
promotion of cancer development (Karmouty-Quintana et al.,
2012; Huerter et al., 2016; Sepúlveda et al., 2016). Furthermore,
Zhou et al. (2011) have shown that A2BAR genetic removal
slightly affects acute lung injury but reduces lung fibrosis,
supporting a pro-fibrotic role for this receptor.
In our study, the A2BAR selective agonist regulated the gene
transcription of different EMT-transcription factors (EMT-TFs).
EMT is a complex process regulated by the orchestration of
several transcription factors. Among these EMT-TFs, ZEB1,
Snail and Slug (SNAI2) are the major transcription factors
involved in the promotion of the EMT process in A549 cells,
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FIGURE 8 | Schematic representation of the effects and the intracellular signals activated by the A2BAR stimulation in the absence (left) or presence (right) of
TGF-β1. The A2BAR activates cAMP/PKA pathways and ERK1/2 phosphorylation. The extent of the activation changes in the presence of the TGF-β1 cytokine
(bold arrow), causing different effects on the expression of transcription factors and markers related to EMT. The receptor activation increases the EMT process
(left), and counteracts the TGF-β1-induced EMT (right).
as previously reported (Ji et al., 2016). A2BAR stimulation did
not affect significantly the expression of Snail and TWIST,
other master genes of EMT. However, A2BAR activation
modulate the expression of Slug and, to a lesser extent, that
of ZEB1, which are commonly considered the major actors in
myofibroblast differentiation and fibrogenesis (Lamouille et al.,
2014). Furthermore, Slug expression has been correlated to direct
repression of E-cadherin expression (Choi et al., 2007). This
evidence was in accordance with the increase in E-cadherin
induced by A2BAR stimulation.
The EMT-TFs are regulated by the activation of different
intracellular pathways, which in turn regulate the balance
between the epithelial and mesenchymal markers. ERK1/2,
GSK3β, p38, STAT3, and cAMP are only few of all the proteins
involved in the promotion/inhibition of EMT (Nieto et al., 2016).
In our cellular model, activation of the cAMP/PKA axis promoted
opposite effects depending on the levels of intracellular the
cAMP. Low concentrations led to a slight promotion or no effects
on epithelial/mesenchymal markers; conversely, high levels of
cAMP could counteract EMT progression. In accordance with
our results, it has been reported that cAMP/PKA activation could
exert opposite effects on EMT (Zhang et al., 2006a,b; Nadella
et al., 2008; Shaikh et al., 2012; Lambers et al., 2015) that could
be ascribed to the different cell models, type of EMT inducer
and maximum levels of intracellular cAMP obtained (Weng et al.,
2015).
A2BAR activation increases the intracellular cAMP levels and
promotes the phosphorylation of ERK 1/2 (Grant et al., 2001;
Zhou et al., 2017). In this respect, we hypothesize that the
controversial role of A2BAR in promoting EMT or reversing
TGF-β1-induced EMT could be ascribed to the different balance
of the intracellular pathways activated. The activation of other
GPCRs coupled to different G proteins has been reported to elicit
opposite effects on EMT. Zhang et al. (2016) have demonstrated
that norepinephrine, which activates Gs protein, induces the
epithelial-mesenchymal transition in A549 cells; similarly, the
P2X7 stimulation, which activates the PI3K/Akt and ERK1/2
signaling pathways, promotes the mesenchymal phenotype in
epithelial renal cells (Zuccarini et al., 2017). A2AARs have been
reported to modify the epithelial/mesenchymal phenotype in
renal cells by downregulating TGF-β1-induced EMT (Zuccarini
et al., 2017) in accordance with the effects elicited by A2BAR
activation in our cellular model when the cytokine was present.
TGF-β1 activates both Smad signaling and non-Smad signaling
including the ERK pathway, critically regulating EMT (Xie et al.,
2004). A2BAR stimulation could counteract cytokine-induced
EMT, reducing the transition progression. These effects were
correlated with a robust increase in cAMP production and with a
concomitant decrease in ERK phosphorylation. In this respect,
we could speculate that the increase in the cAMP, mediated
by A2BAR activation, could counteract the cytokine-mediated
effects on EMT. This is in accordance with the ability of other
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Gs coupled receptors (i.e., A2AAR) or cAMP inducers (i.e.,
forskolin, 8-Br-cAMP) to prevent TGF-β1-mediated EMT
(Zhang et al., 2006a,b; Zuccarini et al., 2017). It should
also be considered that cAMP/PKA has a negative effect
on TGF-β induced pERK 1/2, but only when the cytokine
downstream pathways are highly expressed (Weng et al.,
2015). This mechanism could explain the reduction in ERK1/2
phosphorylation in the presence of the A2BAR agonist.
The modulation of cAMP production and ERK
phosphorylation could be affected by internalization or
desensitization processes of the receptor. Several GPCRs employ
a variety of signaling mechanisms to exert their functions.
The production of second messengers, such as cAMP, is the
results of the receptor-G protein coupling. However, other
signals produced in conjunction with, or even independent of
heterotrimeric G protein could be activated. It is well known
that the arrestins, a family of four GPCR-binding proteins
originally described for their role in the GPCR desensitization,
have been found to interact with Src family kinases and to
serve as scaffolds for activation of ERK1/2 and c-Jun N-terminal
kinase 3 mitogen-activated protein kinases (Ferguson, 2001;
Luttrell, 2005; Lee et al., 2008). Thus, the desensitization could
represent a mechanism to maintain the activation of G-protein
independent pathways. The activation of the A2BAR for long
time produced the desensitization of the receptor. This may
be another mechanism through which A2BAR mediate the
ERK phosphorylation favoring the EMT traits. Conversely,
the TGF-β1 was able to reduce the agonist-induced A2BAR
desensitization, maintaining the ability of A2BAR to produce
cAMP that negatively affected EMT process. These data could
better highlight the controversial role of A2BAR in the EMT.
In different pathological status in which adenosine raise to
micromolar concentration, the extracellular microenvironment
and the localization of the receptor could interfere with the levels
of the activated intracellular signaling shifting the balance in
favor of or against the EMT.
In our cellular model, A2BAR activation was able to induce
partial EMT; however, it was not sufficient to promote a
complete epithelial-mesenchymal transformation of the lung
cells. The involvement of the cAMP/PKA and MAPK/ERK
signaling pathways was demonstrated by the use of selective
inhibitors. The EMT traits, in the presence of A2BAR agonist
was enhanced by PKA inhibition and decreased by the ERK1/2
phosphorylation blockade. Furthermore, the pretreatment with a
PKA inhibitor did not enhance receptor effects on TF expression.
Conversely, the presence of the MEK inhibitor completely
counteracted the A2B-mediated increase in Slug and ZEB1
gene expression, demonstrating the involvement of MAPK/ERK
pathway activation in A2BAR-mediated EMT induction.
CONCLUSION
For the first time, these results highlight the possibility that
A2BAR is one of the numerous receptors that could be involved
in EMT regulation. Although the expression of the other
adenosine receptor subtypes are low, in physiological condition
the involvement of all the AR in the EMT regulation could
not be excluded. A2BAR activation is not enough to trigger a
complete transition; it can affect the expression of the epithelial
and mesenchymal markers promoting EMT traits. These effects
are related to the ability of A2BAR to modify the balance
between cAMP/PKA and MAPK/ERK activation. The presence
of extracellular cytokines that activate the transition could change
the balance and levels of these two intracellular pathways,
shifting the effects exerted by the receptor stimulation on
EMT trigger and maintenance. Thus, the A2BAR seems to act
as an EMT regulator rather than a main actor in the EMT
induction. Although the EMT is a complex machinery and
further investigation are needed to better elucidate the effects
of adenosine and the contribution of the other AR subtypes
in physiopathological conditions, herein, for the first time, the
A2BAR was shown to be related to the EMT process, highlighting
its potential role as pharmacological target in EMT-related
pathologies.
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